A child could recognize that this drug is going to go to market. It consistently doubles keytruda effectiveness across all indications at a minimum-in this latest case 7x. It even does even better at the higher dose that showed no additional side effects. It is very clear it’s going to get reg approval ultimately.
Ann: Positive results in TACTI-003 for 1L HNSCC cohort B patients, page-19
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.8¢ |
Change
-0.018(5.22%) |
Mkt cap ! $472.0M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.5¢ | $504.9K | 1.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 206338 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 107290 | 18 |
View Market Depth
| Last trade - 11.48am 02/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |